Pacer Advisors Inc. Buys 680,818 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Pacer Advisors Inc. boosted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4,020.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 697,753 shares of the medical equipment provider’s stock after acquiring an additional 680,818 shares during the period. Pacer Advisors Inc.’s holdings in Zimmer Biomet were worth $62,742,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Key Financial Inc boosted its holdings in Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 163 shares during the last quarter. Cullen Frost Bankers Inc. boosted its holdings in Zimmer Biomet by 66.7% in the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 116 shares during the last quarter. Root Financial Partners LLC bought a new stake in Zimmer Biomet in the third quarter valued at approximately $31,000. Flagship Harbor Advisors LLC bought a new stake in Zimmer Biomet in the fourth quarter valued at approximately $32,000. Finally, Grove Bank & Trust boosted its holdings in Zimmer Biomet by 431.6% in the fourth quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 328 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on ZBH. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a report on Tuesday, February 10th. Barclays reduced their target price on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a report on Wednesday, April 29th. Citizens Jmp dropped their price target on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a research note on Wednesday, April 29th. Leerink Partners initiated coverage on Zimmer Biomet in a research note on Monday, April 13th. They issued a “hold” rating and a $101.00 price target on the stock. Finally, UBS Group reissued a “sell” rating and issued a $89.00 price target on shares of Zimmer Biomet in a research note on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $102.80.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares of the company’s stock, valued at $967,803.84. This represents a 20.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.28% of the stock is owned by insiders.

Zimmer Biomet Price Performance

Shares of ZBH opened at $82.67 on Thursday. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $108.29. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. The business’s 50 day moving average price is $90.15 and its two-hundred day moving average price is $91.72. The firm has a market cap of $15.99 billion, a PE ratio of 21.47, a price-to-earnings-growth ratio of 1.93 and a beta of 0.48.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The firm had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.07 billion. During the same period in the previous year, the firm earned $1.81 earnings per share. The company’s revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.47 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend was Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is presently 24.94%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.